University of Michigan
Ann Arbor, Michigan, United States
150 recruiting
Showing 1–20 of 427 trials
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled420 locationsNCT06119581
Recruiting
Precision-Based Genomics in Prostate Cancer
Prostate Cancer
National Cancer Institute (NCI)2,000 enrolled11 locationsNCT04706663
Recruiting
Phase 3
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
COVID-19 Infection
Pfizer300 enrolled147 locationsNCT07013474
Recruiting
Not Applicable
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University750 enrolled7 locationsNCT06906627
Recruiting
ASSESS ALL ALS Study
Amyotrophic Lateral Sclerosis
St. Joseph's Hospital and Medical Center, Phoenix2,000 enrolled32 locationsNCT06578195
Recruiting
Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Pfizer80 enrolled33 locationsNCT06057402
Recruiting
Not Applicable
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University420 enrolled7 locationsNCT06906640
Recruiting
PREVENT ALL ALS Study
Amyotrophic Lateral Sclerosis
St. Joseph's Hospital and Medical Center, Phoenix600 enrolled32 locationsNCT06581861
Recruiting
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
Parkinson's Disease
Bayer300 enrolled26 locationsNCT07330258
Recruiting
Phase 2Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.153 enrolled35 locationsNCT07159841
Recruiting
Phase 2
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Cushing's Disease
H. Lundbeck A/S18 enrolled27 locationsNCT06471829
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled17 locationsNCT05768932
Recruiting
Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim120 enrolled102 locationsNCT07107945
Recruiting
Mucopolysaccharidosis VII Disease Monitoring Program
Mucopolysaccharidosis VIIMPS VIIMPS 7+1 more
Ultragenyx Pharmaceutical Inc50 enrolled14 locationsNCT03604835
Recruiting
Not Applicable
Michigan Men's Diabetes Project III(MenDIII): Mind and Motion
DepressionDiabetes Mellitus, Type 2Depressive Symptoms
University of Michigan80 enrolled1 locationNCT06574035
Recruiting
Not Applicable
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Open Midline Laparotomy
C. R. Bard477 enrolled45 locationsNCT03911700
Recruiting
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Parkinson Disease
Michael J. Fox Foundation for Parkinson's Research4,500 enrolled50 locationsNCT04477785
Recruiting
Not Applicable
Michigan Weight Navigation Program (MiWeigh) Study
Obesity
University of Michigan500 enrolled1 locationNCT07465341
Recruiting
Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521